STAT+ Report: Corporate Medicine Crackdown Threatens Telehealth Business Models

State Crackdowns on Corporate Medicine Upend Telehealth Models

STAT+ highlights the growing legal challenges to telehealth business models as states enforce corporate practice of medicine laws. This crackdown puts the virtual Rx industry in a difficult position, forcing a re-evaluation of operational strategies. For biotech and digital health investors, the Stat Medical implications are immediate: companies that built billion-dollar valuations on centralized prescribing platforms now face existential questions about whether their core structures violate century-old statutes designed to keep corporations out of the exam room.

Key Takeaways

• State enforcement of Corporate Practice of Medicine (CPOM) laws is intensifying, directly challenging the business models of many telehealth and virtual prescription companies.
• Legal battles are emerging over the fundamental structure of telehealth operations and physician oversight, with significant penalties for violations.
• States including California, Texas, and New York are leading enforcement efforts, mandating that only licensed physicians can own and control medical practices.
• The virtual Rx industry is actively pushing back against these regulatory and legal challenges through litigation and operational restructuring.
• Companies face increased compliance costs and potential limitations on service offerings as they navigate the evolving legal landscape.

Why Are States Cracking Down on Corporate Medicine Now?

The corporate practice of medicine doctrine refers to a set of laws developed over the last century to prevent unlicensed entities or corporations from practicing medicine or employing physicians to do so on their behalf. These statutes were designed to preserve physician independence and prevent commercial interests from influencing medical judgment. For decades, enforcement was sporadic. The telehealth boom changed that.

States with strict CPOM laws rigorously enforce the prohibition against corporate ownership of medical practices. California, Texas, and New York mandate that only licensed physicians can own and control medical practices, and they impose significant penalties for violations. These three states have become focal points for enforcement actions that directly target the telehealth industry's operational structures, but the ripple effects extend nationwide. A 50-state guide from Permit Health details how CPOM prohibitions vary across jurisdictions, revealing that the legal risk is not confined to a handful of states.

The current wave of enforcement has caught many virtual care companies off guard. Platforms that built their businesses around centralized clinical decision-making and corporate oversight of prescribing practices are now facing scrutiny over whether their models comply with state-level CPOM prohibitions. The legal theory underlying these challenges holds that when corporations effectively control medical decision-making, they are practicing medicine without a license. State attorneys general and medical boards have begun filing suits and issuing cease-and-desist orders, arguing that algorithmic prescribing guidance and corporate clinical protocols amount to the unauthorized practice of medicine.

How Are Telehealth Business Models Being Disrupted?

The virtual Rx boom that defined much of the past decade in digital health is now facing significant headwinds. Companies that scaled rapidly by building technology platforms connecting patients with prescribers are discovering that their fundamental business structures may violate longstanding state laws. The tension between corporate investment and physician independence has become the central fault line in this dispute.

Operations built on centralized formularies, algorithmic prescribing guidance, and corporate protocols for clinical encounters are particularly vulnerable. When a company's business model depends on standardizing care delivery across thousands of encounters, states may view that standardization as corporate control over medical judgment. The consequences for non-compliance can include injunctions, fines, and the forced restructuring of operations. For investors, the risk is not merely regulatory, it is structural: if the platform model itself is unlawful, no amount of compliance spending can fix it.

Industry observers note that the crackdown is forcing companies to reconsider how they structure physician relationships, clinical workflows, and revenue models. Some platforms are exploring shifts toward independent practice association models or direct physician employment arrangements that preserve greater clinical autonomy. Others are challenging the laws themselves through litigation, arguing that modern telehealth delivery requires structures that older statutes never anticipated. The outcome will determine whether the virtual Rx sector can sustain its current growth trajectory or must fundamentally reinvent itself.

What Is the Industry Doing to Fight Back?

The virtual Rx industry is pushing back against these regulatory and legal challenges on multiple fronts. Companies are filing lawsuits arguing that CPOM laws are outdated and fail to account for the realities of technology-enabled care delivery. Some are seeking legislative changes that would create exemptions or safe harbors for telehealth platforms that maintain appropriate physician oversight.

The Mochi suit includes in its state law unfair competition claims allegations of unlawful corporate control of the practice of medicine and prescription authority. This case exemplifies the broader legal strategy being employed by companies seeking to establish precedent that modern telehealth structures can coexist with physician independence requirements. The litigation is being closely watched by digital health investors and operators as a bellwether for the sector's legal viability.

State legislatures are also debating whether to strengthen CPOM enforcement or create new frameworks for virtual care. As consolidation and prices climb in healthcare, some policy briefs argue that new limits on management services organizations could tilt the market further toward hospitals. The outcome of these debates will shape the competitive dynamics of telehealth for years to come. STAT has built its reputation covering exactly these kinds of critical industry shifts, providing indispensable insights on the technologies, personalities, and political forces driving massive changes in the life science industry.

Frequently Asked Questions

Related coverage

• ASCO 2026: Key Takeaways on Cancer Care Barriers and New Treatments